Funder: Breakthrough T1D
Due Dates: November 5, 2025 (LOI) | January 20, 2026 (Full proposal)
Funding Amounts: Up to $750,000 total over 2 years; smaller budgets considered; 10% indirect costs allowed (SRA only).
Summary: Supports studies on how insulin dose and its reduction affect acute and long-term outcomes in people with type 1 diabetes, aiming to inform clinical care and therapy development.